Corporate overview presentation highlights partnered programs and milestones
Prothena highlighted partnered late-stage programs, led by Roche’s Phase 3 prasinezumab trial in early Parkinson’s disease, with primary completion expected in 2029.
Novo Nordisk’s coramitug (PRX004) in ATTR cardiomyopathy remains in Phase 3, with CLEOPATTRA ongoing and primary completion expected in 2029.
Bristol Myers Squibb-linked PRX019 completed Phase 1; Prothena flagged a potential $55 million milestone tied to a development decision by year-end 2026.
Prothena also pointed to up to $105 million in clinical milestones by year-end 2026, including a $50 million Phase 3 enrollment milestone for coramitug.
Shareholder returns included $22.3 million of repurchases in the first half of 2026 under a program authorizing up to $100 million through Dec. 31, 2026.
PRTA•
